Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

2-Anilino-4-(Heterocyclic) Amino-Pyrimidines

a technology of aminopyrimidines and aminopyrimidines, which is applied in the field of 2arylamino4(heterocyclic) aminopyrimidines, can solve the problems of symptomatic heart failure, reduced cardiac output, and impaired diastolic and/or systolic function, and achieves the effect of slowing the progression of heart failure and improving myocardial contraction and relaxation performan

Inactive Publication Date: 2007-12-20
DJUNG JANE FAR JINE +3
View PDF10 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] The present invention meets the aforementioned needs in that it has been found that certain 2-arylamino-4-(heterocyclic)aminopyrimidines are effective for inhibiting Protein Kinase C-alpha (PKC-α) thereby improving myocardial contraction and relaxation performance and slowing the progression of heart failure.
[0031] The third major aspect of the present invention relates to methods of use. As described herein below, the PKC-α inhibitors of the present invention are important for improving myocardial contraction and relaxation performance and thereby slowing the progression of heart failure and their administration to humans is, therefore, an effective treatment for humans suffering from acute heart failure.

Problems solved by technology

While the root cause of heart failure is multifaceted, it uniformly is marked by impaired diastolic and / or systolic function and can be accompanied by chamber enlargement which ultimately manifest in symptomatic heart failure (fatigue, pulmonary edema, circulatory congestion, etc.)
Patients with acute decompensated heart failure (ADHF) are a treatment challenge to physicians and can present with volume overload and / or diminished cardiac output.
Despite the widespread use of these agents, long-term safety and benefit of these drugs have been questioned.
Therefore, there is a limited means to treat patients with various forms and stages of heart failure and there is incentive to develop novel, safe and effective treatments to prevent or treat patients with symptoms of heart failure, acute exacerbation of heart failure and chronic heart failure and other cardiovascular diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
  • 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
  • 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines

Examples

Experimental program
Comparison scheme
Effect test

example 1

N2-(3-chlorophenyl)-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (4)

[0206] Preparation of 2-(methylthio)pyrimidine-4(3H-one (1): To a solution of sodium hydroxide (6.24 g, 156.07 mmol) in H2O (55 mL) at room temperature is added thiouridine (10 g, 78.03 mmol). The resulting mixture is stirred at room temperature for 20 min. Methyl iodide (5.45 mL, 87.40 mmol) in THF (10 mL) is added dropwise slowly and the mixture is stirred at room temperature for 18 hours. A white solid forms upon acidifying the mixture to pH 5 with glacial acetic acid. The mixture is allowed to stand at 0° C. (ice bath) for 2 hours and filtered to afford 7.4 g (67% yield) of the desired compound as a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 2.45 (s, 3H), 6.07 (d, J=6.6 Hz, 1H), 7.85 (d, J=6.6 Hz, 1H).

[0207] Preparation of 2-(3-chlorophenylamino)pyrimidin-4(3H)-one (2): To 2-(methyl-thio)pyrimidine-4(3H)-one, 1, (4.88 g, 34.37 mmol) in diglyme (20 mL) is added 3-chloroaniline (4.3 mL, 68.74 mmol). The re...

example 2

N2-[3-(Pyridin-3-yl)-phenyl]-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (7)

[0267] Preparation of 2-chloro-N-(3-morpholinopropyl)pyrimidin-4-amine (5): To 2,4-dichloropyrimidine (5.0 g, 33.5 mmol), diisoproylethylamine (5.85 ml, 33.5 mmol) in 50 ml of a 1:1 mixture of n-butanol and water is added 3-morpholinopropan-1-amine (4.90 ml, 33.5 mmol). The resulting mixture was stirred for 18 hours at room temperature. The mixture is then concentrated in vacuo, diluted with 30 mL water and extracted with EtOAc (3×50 ml). Combined organic layers are washed with saturated NaHCO3 (2×20 ml) and saturated NaCl (2×20 ml), then dried over magnesium sulfate. The residue is purified over silica (25% EtOAc in Hexanes) to afford 4.5 g (51% yield) of the desired product. 1H NMR (CDCl3, 300 MHz): δ (ppm) 1.83 (q, J=2.0 Hz, 2H), 2.54 (m, 6H), 3.53 (bs, 2H), 3.79 (t J=4.7 Hz, 4H), 6.24 (d, J=5.67 Hz, 1H), 6.92 (bs, 1H), 7.99 (bs, 1H). MS (ESI, pos. ion) m / z: 257 (M+1).

[0268] Preparation of 3-(py...

example 3

N2-Biphenyl-3-yl-N4-(3-morpholin-4-yl-propyl)-pyrimidine-2,4-diamine (10)

[0326] Preparation of 2-(3-biphenylamino)pyrimidin-4(3H)-one (8): To 2-(methylthio)-pyrimidine-4(3H)-one (790 mg, 5.5 mmol) in 5 mL of diglyme is added 3-amino-biphenyl (1.91 g, 11.2 mmol). The resulting mixture is stirred at reflux for 18 hours. The mixture is cooled to room temperature and hexanes are added to form a precipitate which is collected by filtration to afford 1.34 g (92% yield) of the desired compound which is used without purification. MS (ESI, pos. ion) m / z: 264 (M+1).

[0327] Preparation of 4-chloro-N-(3-biphenyl)pyrimidin-2-amine (9): To 2-(3-biphenyl-amino)pyrimidin-4(3H)-one (1.34 g, 5.0 mmol), and N,N-dimethylaniline (1.5 mL) is added 10 mL of phosphorus oxychloride. The resulting mixture is heated at reflux for 1 hour, cooled to room temperature and concentrated in vacuo. The residue is neutralized with 1M NaOH (aqueous). The organics are extracted t portions of EtOAc (2×50 mL). The combin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of U.S. provisional application No. 60 / 813,956, filed Jun. 15, 2006, the entirety of which is incorporated herewith by reference.FIELD OF THE INVENTION [0002] The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines which are inhibitors of Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure. BACKGROUND OF THE INVENTION [0003] Many biologically active substances, for example, hormones, neurotransmitters and peptides are known to exert functions via intracellular mediators suc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377A61K31/506C07D413/02C07D403/02
CPCC07D239/48C07D401/12C07D401/14C07D417/12C07D403/14C07D413/12C07D403/12A61P1/02A61P13/02A61P13/12A61P25/00A61P27/02A61P29/00A61P3/00A61P35/00A61P3/06A61P43/00A61P7/02A61P9/00A61P9/04A61P9/06A61P9/08A61P9/10A61P9/12A61P9/14A61P3/10A61K31/505
Inventor DJUNG, JANE FAR-JINEGOLEBIOWSKI, ADAMHUNTER, JACK A.SHRUM, GARY P.
Owner DJUNG JANE FAR JINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com